Patents by Inventor Larry S. McDaniel

Larry S. McDaniel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040077847
    Abstract: The present invention relates to pneumococcal genes, portions thereof, expression products therefrom and uses of such genes, portions and products; especially to genes of Streptococcus pneumoniae, e.g., the gene encoding pneumococcal surface protein A (PspA), i.e., the pspA gene, the gene encoding pneumococcal surface protein A-like proteins, such as pspA-like genes, e.g., the gene encoding pneumococcal surface protein C (PspC), i.e., the pspC gene, portions of such genes, expression products therefrom, and the uses of such genes, portions thereof and expression products therefrom.
    Type: Application
    Filed: November 19, 2002
    Publication date: April 22, 2004
    Inventors: David E. Briles, Larry S. McDaniel, Edwin Swiatlo, Janet Yother, Marilyn J. Crain, Susan Hollingshead, Rebecca Tart, Alexis Brooks-Walter
  • Patent number: 6592876
    Abstract: PspAs, portions thereof, DNA therefor, and immunological compositions, primers and probes based thereon are disclosed claimed.
    Type: Grant
    Filed: September 15, 1995
    Date of Patent: July 15, 2003
    Assignee: UAB Research Foundation
    Inventors: David E. Briles, Larry S. McDaniel, Edwin Swiatlo, Janet Yother, Alexis Brooks-Walter
  • Patent number: 6500613
    Abstract: The present invention relates to pneumococcal genes, portions thereof, expression products therefrom and uses of such genes, portions and products; especially to genes of Streptococcus pneumoniae, e.g., the gene encoding pneumococcal surface protein A (PspA), i.e., the pspA gene, the gene encoding pneumococcal surface protein A-like proteins, such as pspA-like genes, e.g., the gene encoding pneumococcal surface protein C (PspC), i.e., the pspC gene, portions of such genes, expression products therefrom, and the uses of such genes, portions thereof and expression products therefrom.
    Type: Grant
    Filed: September 16, 1996
    Date of Patent: December 31, 2002
    Assignee: University of Alabama at Birmingham
    Inventors: David E. Briles, Larry S. McDaniel, Edwin Swiatlo, Janet Yother, Marilyn J. Crain, Susan Hollingshead, Rebecca Tart, Alexis Brooks-Walter
  • Publication number: 20020102242
    Abstract: Plasmid DNA encoding at least one pneumococcal antigen or epitope of interest and methods for making and using such a plasmid are disclosed and claimed. The epitope of interest can be PspA or a fragment thereof. Compositions containing the plasmid DNA are useful for administration to a host susceptible to pneumococcal infection for an in vivo response, such as a protective response, or for generating useful antibodies. The inventive plasmid can also be transfected into cells for generating antigens or epitopes of interest in vitro. And the inventive plasmid can be prepared by isolating DNA (coding for: promoter, leader sequence, epitope of interest and terminator), and performing a three-way ligation. More particularly, administration of DNA encoding pneumococcal antigens or epitopes of interest and compositions therefor for eliciting and immunological response against S. pneumoniae, such as a protective response preventive of pneumococcal infection, are disclosed and claimed.
    Type: Application
    Filed: April 27, 2001
    Publication date: August 1, 2002
    Inventors: David E. Briles, Larry S. McDaniel, David T. Curiel
  • Patent number: 6231870
    Abstract: Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 15, 2001
    Assignee: UAB Research Foundation
    Inventors: David E. Briles, Larry S. McDaniel, Masafumi Yamamoto, Hiroshi Kiyono
  • Patent number: 6232116
    Abstract: Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 15, 2001
    Assignee: University of Alabama at Birmingham Research Foundation
    Inventors: David E. Briles, Larry S. McDaniel, Masafumi Yamamoto, Hiroshi Kiyono
  • Patent number: 6004802
    Abstract: Oral or peroral administration, including intragastrically, of killed whole pneumococci, lysate of pneumococci and isolated and purified PspA, as well as immunogenic fragments thereof, particularly when administered with an adjuvant such as cholera toxin provides protection in a host, animal or human, against pneumococcal infection, including colonization, and systemic infection, such as sepsis. The ability to elicit protection against pneumococcal colonization in a host prevents carriage among immunized individuals, which can lead to elimination of disease from the population as a whole.
    Type: Grant
    Filed: May 30, 1996
    Date of Patent: December 21, 1999
    Assignee: University of Alabama at Birmingham
    Inventors: David E. Briles, Larry S. McDaniel, Masafumi Yamamoto, Hiroshi Kiyono
  • Patent number: 5997882
    Abstract: Regions of the PspA protein of the R.times.1 strain of Streptococcus pneumoniae have been identified as containing protection-eliciting epitopes which are cross-reactive with PspAs of other S. pneumoniae strains and which is cross-protective. One region comprises the 68-amino acid sequence extending from amino acid residues 192 to 260 of the R.times.1 PspA strain while another region comprises the C-terminal amino acid sequence extending from amino acid residues 293 to 588 of the R.times.1 PspA strain.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 7, 1999
    Assignee: UAB Research Foundation
    Inventors: David E. Briles, Janet L. Yother, Larry S. McDaniel
  • Patent number: 5980909
    Abstract: Regions of the PspA protein of the Rx1 strain of Streptococcus pneumoniae have been identified as containing protection-eliciting epitopes which are cross-reactive with PspAs of other S. pneumoniae strains and which is cross-protective. One region comprises the 68-amino acid sequence extending from amino acid residues 192 to 260 of the Rx1 PspA, another region comprises the C-terminal amino acid sequence extending from amino acid residues 293 to 588 of the Rx1 PspA, while a third region comprises the N-terminal amino acid sequence extending from amino acid residues 1 to 115 of the Rx1 PspA.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: November 9, 1999
    Assignee: UAB Research Foundation
    Inventors: David E. Briles, Janet L. Yother, Larry S. McDaniel
  • Patent number: 5965141
    Abstract: A region of the PspA protein of the Rx1 strain of Streptococcus pneumoniae has been identified as containing protection-eliciting epitopes which are cross-reactive with PspAs of other S. pneumoniae strains and which is cross-protective. The region comprises the 68-amino acid sequence extending from amino acid residues 192 to 260 of the Rx1 PspA strain.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: October 12, 1999
    Assignee: UAB Research Foundation
    Inventors: David E. Briles, Janet L. Yother, Larry S. McDaniel, Hong-Yin Wu
  • Patent number: 5476929
    Abstract: A purified pneumococcal surface protein A (PspA) comprises a truncated form of the PspA protein which is immunoprotective and contains the protective epitopes of PspA. The PspA protein is soluble in physiologic solution and lacks at least the cell membrane anchor region of the whole protein. The protein is formed by insertion-duplication of mutagenesis of S. pneumoniae with pspA gene and expression of the truncated protein into the growth medium.
    Type: Grant
    Filed: June 3, 1993
    Date of Patent: December 19, 1995
    Assignee: UAB Research Foundation
    Inventors: David E. Briles, Janet L. Yother, Larry S. McDaniel